Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients

References

• Dracini X, Dibra A, Celiku E, et al. Actual status of preoperative diagnosis of thyroid cancer in Albania. G Chir 2013;34:14–7
   Google Scholar
• Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010;22:395–404
   PubMed Web of Science ®Google Scholar
• Cossu A, Budroni M, Paliogiannis P, et al. Epidemiology of thyroid cancer in an area of epidemic thyroid goiter. J Cancer Epidemiol 2013;2013:584768
   Google Scholar
• Han JM, Kim WB, Yim JH, et al. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid 2012;22:784–90
   PubMed Web of Science ®Google Scholar
• Husson O, Haak HR, van Steenbergen LN. Rising incidence, no change in survival and decreasing mortality from thyroid cancer in The Netherlands since 1989. Endocr Relat Cancer 2013;20:263–71
   Google Scholar
• Ito Y, Nikiforov YE, Schlumberger M, Vigneri R. Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol 2013;9:178–84
   PubMed Web of Science ®Google Scholar
• Kachuri L, De P, Ellison LF, Semenciw R. Cancer incidence, mortality and survival trends in Canada, 1970–2007. Chronic Dis Inj Can 2013;33:69–80
   Google Scholar
• Aliyev A, Ylmaz S, Ozhan M, et al. FDG PET/CT in the detection of metastases in a patient with Tg and 131I WBS negative follicular thyroid cancer. Clin Nucl Med 2013;38:226–7
   Google Scholar
• Hackshaw A, Kadalayil L, Mallick U. Well-being after radiation therapy in thyroid cancer. N Engl J Med 2013;368:685–6
   Google Scholar
• Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer 2004;11:97–116
   Google Scholar
• Sengoz T, Surucu E, Demir Y, Derebek E. The effects of the factors related to the patient and the disease on the performance of ablation therapy in patients with differentiated thyroid cancer who have received I-131 ablation therapy. Mol Imaging Radionucl Ther 2012;21:103–9
   Google Scholar
• Zosin I, Golu I, Cornianu M, et al. Some clinical aspects in chronic autoimmune thyroiditis associated with thyroid differentiated cancer. Maedica (Buchar) 2012;7:277–83
   Google Scholar
• Podoba J. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer. Bratisl Lek List 2010;111:38–40
   Google Scholar
• Rajkovaca Z, Kovacevic P, Stanetic M, Ristic S. Assessment of recombinant human thyrotropin application in following-up patients with well-differentiated thyroid carcinoma. Vojnosanit Pregl 2012;69:941–6
   Google Scholar
• Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002;12:37–43
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87:1490–8
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Robbins RJ, Spencer CA. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433–41
   PubMed Web of Science ®Google Scholar
• Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242–7
   PubMed Web of Science ®Google Scholar
• Valle LA, Gorodeski Baskin RL, Porter K, et al. In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin. Thyroid 2013;23:185–93
   PubMed Web of Science ®Google Scholar
• Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5686–90
   Web of Science ®Google Scholar
• Kloos RT. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J Clin Endocrinol Metab 2010;95:5241–8
   PubMed Web of Science ®Google Scholar
• Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:5047–57
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214
   PubMed Web of Science ®Google Scholar
• Lang BH, Tang AH, Wong KP, et al. Significance of size of lymph node metastasis on postsurgical stimulated thyroglobulin levels after prophylactic unilateral central neck dissection in papillary thyroid carcinoma. Ann Surg Oncol 2012;19:3472–8
   Google Scholar
• Lang BH, Wong KP, Wan KY, et al. Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann Surg Oncol 2012;19:1257–63
   Google Scholar
• Raef H, Alfadhli E, Al-Hajjaj A, et al. High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission. Ann Saudi Med 2008;28:277–81
   Google Scholar
• Clayman GL, Agarwal G, Edeiken BS, et al. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid 2011;21:1309–16
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2007;66:58–64
   PubMed Web of Science ®Google Scholar
• Jeon MJ, Park JW, Han JM, et al. Serum antithyroglobulin antibodies interfere with thyroglobulin detection in fine-needle aspirates of metastatic neck nodes in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013;98:153–60
   Google Scholar
• Legakis I, Manousaki M, Detsi S, Nikita D. Thyroid function and prevalence of anti-thyroperoxidase (TPO) and anti-thyroglobulin (Tg) antibodies in outpatients hospital setting in an area with sufficient iodine intake: influences of age and sex. Acta Med Iran 2013;51:25–34
   Google Scholar
• Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20:1341–9
   PubMed Web of Science ®Google Scholar
• Pelttari H, Valimaki MJ, Loyttyniemi E, Schalin-Jantti C. Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. Eur J Endocrinol 2010;163:757–63
   Google Scholar
• Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays? Clin Endocrinol (Oxf) 2008;68:338–42
   Google Scholar
• Soyluk O, Boztepe H, Aral F, et al. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment. Thyroid 2011;21:1301–8
   PubMed Web of Science ®Google Scholar
• De Amicis F, Perri A, Vizza D, et al. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines. J Cell Physiol 2013;228:2054–62
   Google Scholar
• Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803
   PubMed Web of Science ®Google Scholar
• Poorten VV, Hens G, Delaere P. Thyroid cancer in children and adolescents. Curr Opin Otolaryngol Head Neck Surg 2013;21:135–42
   Google Scholar
• Welsh L, Powell C, Pratt B, et al. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer. J Clin Endocrinol Metab 2013;98:1819–25
   Google Scholar